1. Clinical Overview

Molecule: First-in-class dual incretin agonist targeting GIP + GLP-1 receptors

FDA Approved: Type 2 Diabetes (Mounjaro®) • Chronic Weight Management (Zepbound®)

Classification: Dual incretin • Anti-obesity • Appetite/reward suppression • Glucose-normalizing • Cardiometabolic optimization

Clinical Potency: 15–22% total body weight loss. Superior A1C, lipid, BP improvements.

2. Mechanisms of Action

2.1 GIP Receptor Agonism (Primary Differentiator)

Improved insulin secretion/sensitivity, reduced GLP-1-associated nausea, additive weight-loss synergy, hypothalamic food-reward reduction. More tolerable and potent than GLP-1 alone.

2.2 GLP-1 Receptor Agonism

Appetite suppression, delayed gastric emptying, reduced cravings/caloric intake, lower postprandial glucagon/glucose.

2.3 Dual-Incretin Synergy

GIP + GLP-1 together: multiplicative weight loss, stronger metabolic improvements, higher insulin sensitivity, lower GI side effects, improved energy expenditure. Faster and larger results than semaglutide.

3. Clinical Applications

3.1 Obesity

15–22% body weight loss. Waist circumference, visceral fat. BMI ≥30 or ≥27 with comorbidities. GLP-1 non-responders, post-semaglutide plateau.

3.2 Type 2 Diabetes

HbA1c reduction 2.5–3.0%. Remission in select patients. Lower fasting insulin, improved beta-cell sensitivity. Superior to semaglutide.

3.3 Metabolic Syndrome

Fasting glucose/insulin, HOMA-IR, lipids, blood pressure. Cardiometabolic restoration.

3.4 NAFLD / NASH

Reduced liver fat, improved ALT/AST, lower fibrosis, reduced central adiposity.

3.5 GLP-1 Plateau

Semaglutide plateau, insufficient appetite suppression, poor reward regulation.

4. Administration & Protocols

Period	Dose
Weeks 1–4	2.5 mg weekly
Weeks 5–8	5 mg weekly
Weeks 9–12	7.5 mg weekly
Weeks 13–16	10 mg weekly
Weeks 17–20	12.5 mg weekly
Week 21+	15 mg weekly (max)

Moderate obesity: 7.5–10 mg. Severe: 10–15 mg. Plateau: +2.5 mg increments. Maintenance: 2.5–5 mg or biweekly.
Route: SC (arm, thigh, abdomen). Same day weekly. Rotate sites. No fasting required.

5. Combination Therapy (Peptide Protocol Portal Synergy)

+ Cagrilintide: Most potent appetite synergy — severe obesity, emotional/sugar-reward eating
+ SLU-PP-332: Mitochondrial, UCP-1 thermogenesis, fat oxidation — accelerated recomposition
+ AOD-9604: Stubborn lower abdominal, gluteofemoral, visceral fat
+ Tesofensine: Hedonic hunger — dopamine, cravings, reward regulation
+ MOTS-c / SS-31: Exercise fatigue, mitochondrial dysfunction, metabolic burnout

6. Clinical Decision Trees

Tree 1 — Is Tirzepatide Indicated?

BMI >30 or >27 + comorbidities? → YES

T2DM requiring A1C reduction? → YES

Plateau on semaglutide? → YES

Pancreatitis history? → CAUTION

Severe GI motility disorder? → AVOID

Tree 2 — Dose Escalation

Poor appetite control? → Increase 2.5 mg

GI side effects? → Maintain current

Near goal weight? → Reduce to 2.5–5 mg

Athlete/recomposition? → Maintain 5–7.5 mg

7. Integrated Archetypes

A — High-Impact Fat Loss

Tirzepatide 10–15 mg/wk + SLU-PP-332 + AOD-9604 + MOTS-c weekly
Outcome: Aggressive, rapid fat reduction.

B — Diabetes Optimization

Tirzepatide 5–10 mg/wk + metformin/berberine + Omega-3 + cardiometabolic diet
Outcome: A1C normalization, insulin sensitivity restoration.

C — Appetite Control & Reward Reset

Tirzepatide 5–10 mg + Tesofensine + Cagrilintide (if needed)
Outcome: Elimination of binge-eating patterns.

D — Weight-Loss Maintenance

Tirzepatide 2.5–5 mg/wk + exercise + AOD-9604 + NAD+ metabolic support
Outcome: Stable weight, minimal rebound.

8. Expected Timeline

Week 1–3: Appetite/cravings decrease
Week 4–8: 3–8% body weight reduction
Month 3–6: 10–15% reduction
Month 6–12: Up to 20%+ reduction
Long-term: Improved metabolic health, reduced cardiometabolic risk

9. Contraindications

Absolute

Personal/family MTC history
MEN2 syndrome
Pregnancy / Breastfeeding

Relative

Gastroparesis
Pancreatitis history
Gallbladder disease
Severe GERD
Renal impairment

10. Adverse Effects

Common: Nausea, vomiting, diarrhea/constipation, fatigue, bloating. Less common: Gallbladder complications, pancreatitis (rare), dehydration-related kidney injury. Rare: Hypoglycemia (with insulin/SUs), severe GI motility issues.

11. Monitoring

Weight & waist circumference
A1C & fasting glucose
Lipid panel
Kidney function
Gallbladder symptoms
Hydration & appetite patterns
Reduce insulin/SU doses if diabetic

Legal Disclaimer

This document is provided solely for educational and informational purposes. Tirzepatide and other peptides referenced herein may constitute off-label or investigational use. Peptide Protocol Portal makes no representations or warranties. By using this document, the reader agrees that Peptide Protocol Portal shall not be held liable. Use at your own risk.

References — Tirzepatide

Foundational Incretin Biology

1. Drucker, D. J. GLP-1, GIP metabolic regulation. Cell Metabolism, 27(4), 740–756 (2018).

2. Nauck, M. A., & Meier, J. J. GIP–GLP-1 synergy. Lancet Diabetes Endocrinol, 4(5), 473–482 (2016).

3. Holst, J. J., & Rosenkilde, M. M. GIP/GLP-1 receptor physiology. Physiol Rev, 100(4), 1427–1468 (2020).

4. Samms, R. J., et al. Dual incretin glucose/energy homeostasis. Diabetes, 65(6), 1651–1661 (2016).

Development & Preclinical

5. Frias, J. P., et al. First-in-human LY3298176. Lancet, 392(10160), 2180–2193 (2018).

6. Finan, B., et al. Co-agonist combinatorial signaling. Nat Med, 29(2), 276–284 (2017).

7. Coskun, T., et al. Dual receptor mechanistic basis. Sci Transl Med, 14(671), eabk3442 (2022).

8. Samms, R. J., et al. Thermogenic/metabolic remodeling. Cell Metabolism, 34(4), 573–589 (2022).

SURPASS Trials — T2DM

9. Frias, J. P., et al. SURPASS-1 monotherapy. NEJM, 385(6), 503–515 (2021).

10. Ludvik, B., et al. SURPASS-2 vs semaglutide. NEJM, 385(6), 503–515 (2021).

11. Dahl, D., et al. SURPASS-3 vs insulin degludec. Lancet, 398(10300), 583–598 (2021).

12. Del Prato, S., et al. SURPASS-4 high CV risk. Lancet, 398(10313), 1811–1824 (2021).

13. Ludvik, B., et al. SURPASS-5 + insulin glargine. Diabetes Care, 45(1), 69–77 (2022).

14. Sattar, N., et al. SURPASS-CVOT rationale. Diabetes Obes Metab, 23(11), 2307–2316 (2021).

SURMOUNT Trials — Obesity

15. Jastreboff, A. M., et al. SURMOUNT-1 landmark Phase 3. NEJM, 387, 205–216 (2022).

16. Garvey, W. T., et al. SURMOUNT-2 obese + T2DM. Lancet, 401(10380), 2032–2046 (2023).

17. Wharton, S., et al. SURMOUNT-3 post-lifestyle. Nat Med, 29(10), 1802–1811 (2023).

18. Aronne, L. J., et al. SURMOUNT-4 sustainability. Lancet, 402(10389), 1428–1440 (2023).

Cardiometabolic & Lipid

19. Heise, T., et al. Insulin sensitivity/β-cell. Diabetes Care, 45(3), 641–650 (2022).

20. Sattar, N., et al. Lipids, BP, inflammation. Lancet Diabetes Endocrinol, 10(8), 589–599 (2022).

21. Gastaldelli, A., et al. Liver fat/hepatic insulin. Diabetes Care, 44(9), 2098–2106 (2021).

22. Han, J., et al. Visceral fat/hepatic lipid. Diabetes Obes Metab, 24(6), 1028–1036 (2022).

NAFLD / NASH

23. Kuchay, M. S., et al. Liver fat/metabolic markers. Lancet Gastroenterol Hepatol, 7(11), 983–993 (2022).

24. Rinella, M. E., et al. Dual agonists & NASH. Nat Rev Gastroenterol Hepatol, 19, 187–205 (2022).

Renal

25. Vaduganathan, M., et al. eGFR/renal biomarkers. Lancet Diabetes Endocrinol, 11(1), 17–28 (2023).

26. Thomas, M. C. Renal protection potential. Kidney Int, 103(4), 690–700 (2023).

Safety

27. Frias, J. P., et al. SURPASS safety profile. NEJM, 385, 503–515 (2021).

28. Ludvik, B., et al. Adverse event profiling. Diabetes Care, 45, 69–77 (2022).

29. FDA CDER. Mounjaro™/Zepbound™ approval/safety. FDA, 2022–2024.

Comparative

30. Frías, J. P., et al. vs semaglutide/dulaglutide/SGLT2i. NEJM, 385(6), 503–515 (2021).

31. Nauck, M. A., et al. Dual vs GLP-1-only. Diabetes Obes Metab, 25(S1), 3–17 (2023).

32. Perakakis, N., et al. Metabolic polyagonists evolution. Nat Rev Endocrinol, 18, 765–784 (2022).

Tirzepatide (GIP/GLP-1 Dual Agonist)